专利检索 cpc:"A61K31/223" 第 1 页

1.

发明授权
Topical compositions for the treatment of dermatological disorders 有权

公开(公告)号：US12071397B2

公开(公告)日：2024-08-27

申请号：US17232729

申请日：2021-04-16

申请人： EVOLOGIE LLC

发明人： Gary I. Weinberger , H. Robert Nagel , Richard A. Brown

IPC分类号： C07C279/14 , A61K9/107 , A61K31/194 , A61K31/198 , A61K31/223 , A61K31/60 , A61K47/06 , A61K47/10 , A61K47/14 , A61K47/32

CPC分类号： C07C279/14 , A61K9/107 , A61K31/194 , A61K31/198 , A61K31/223 , A61K31/60 , A61K47/14 , A61K47/06 , A61K47/10 , A61K47/32 , A61K31/198 , A61K2300/00 , A61K31/194 , A61K2300/00 , A61K31/60 , A61K2300/00 , A61K31/223 , A61K2300/00

摘要： The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful for the treatment of dermatological diseases and the symptoms and underlying causes of such dermatological diseases are also disclosed.

2.

发明授权
Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester 有权

公开(公告)号：US11992491B2

公开(公告)日：2024-05-28

申请号：US17258014

申请日：2019-07-02

申请人： Merck Patent GmbH

发明人： Rudolf Moser , Viola Groehn , Ruth Boehni Stamm , Fritz Blatter , Martin Szelagiewicz

IPC分类号： A61K31/519 , A23L33/00 , A23L33/10 , A61K31/223

CPC分类号： A61K31/519 , A23L33/10 , A23L33/40 , A61K31/223 , A23V2002/00

摘要： The present invention refers to a crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester wherein the molar ratio of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester is from 1:0.3 to 1:3.0 (in mol/mol) and/or hydrates and/or solvates thereof as well as to a process of obtaining the same.

3.

发明公开
METHOD FOR MANUFACTURING NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF AND MANUFACTURING INTERMEDIATE OF NOVEL NITROGEN-CONTAINING COMPOUND OR SALT THEREOF 审中-公开

公开(公告)号：US20240108607A1

公开(公告)日：2024-04-04

申请号：US18112423

申请日：2023-02-21

申请人： FUJIFILM Corporation

发明人： Hirofumi FUKUNAGA , Sachiko SHINJO , Daisuke NAKAGAWA , Shinichiro SEKINE , Takayuki YAMAKAWA

IPC分类号： A61K31/4375 , A61K31/145 , A61K31/223 , A61K31/27 , A61K31/395 , A61K31/555 , A61K31/785 , A61K51/00 , C07B59/00 , C07D255/02 , C07D257/02 , C07D471/04 , C07D487/00 , C07F1/08 , C07F5/00

CPC分类号： A61K31/4375 , A61K31/145 , A61K31/223 , A61K31/27 , A61K31/395 , A61K31/555 , A61K31/785 , A61K51/00 , C07B59/00 , C07D255/02 , C07D257/02 , C07D471/04 , C07D487/00 , C07F1/08 , C07F5/00

摘要： A compound represented by Formula [3] or a salt thereof and a method of making the

in the formula, L3 represents a group represented by Formula [2c]

wherein R3c, R4c, R5c and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6; A1 represents any one of the groups represented by Formulae [4] to [9],

wherein * represents a binding position; and R7 represents a carboxyl-protecting group; and m represents an integer of 1 to 3.

4.

发明公开
BENEFITS OF SUPPLEMENTATION WITH N-ACETYLCYSTEINE AND GLYCINE TO IMPROVE GLUTATHIONE LEVELS 审中-公开

公开(公告)号：US20240041812A1

公开(公告)日：2024-02-08

申请号：US18235533

申请日：2023-08-18

申请人： SOCIÉTÉ DES PRODUITS NESTLÉ S.A. , BAYLOR COLLEGE OF MEDICINE

发明人： Stephen Kirnon , Eric Freedland , Rajagopal V. Sekhar

IPC分类号： A61K31/198 , A61K38/05 , A61K31/167 , A61K31/223 , A61K31/341 , A61K38/21 , A61K31/683 , A61K31/27 , A61K45/06 , A61K31/381 , A61K31/205 , A61P39/06 , A23K20/142 , A23K50/50 , A61P21/00 , A61P39/00 , A61P31/18 , A61P29/00 , A61K38/02

CPC分类号： A61K31/198 , A61K38/05 , A61K31/167 , A61K31/223 , A61K31/341 , A61K38/21 , A61K31/683 , A61K31/27 , A61K45/06 , A61K31/381 , A61K31/205 , A61P39/06 , A23K20/142 , A23K50/50 , A61P21/00 , A61P39/00 , A61P31/18 , A61P29/00 , A61K38/02

摘要： Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

5.

发明授权
Benefits of supplementation with n-acetylcysteine and glycine to improve glutathione levels 有权

公开(公告)号：US11730711B2

公开(公告)日：2023-08-22

申请号：US17175111

申请日：2021-02-12

申请人： SOCIÉTÉ DES PRODUITS NESTLÉ S.A. , BAYLOR COLLEGE OF MEDICINE

发明人： Stephen Kirnon , Eric Freedland , Rajagopal V. Sekhar

IPC分类号： A61K31/198 , A61K38/05 , A61K31/167 , A61K31/223 , A61K31/341 , A61K38/21 , A61K31/683 , A61K31/27 , A61K45/06 , A61K31/381 , A61K31/205 , A23K20/142 , A23K50/50 , A61P21/00 , A61P39/00 , A61P31/18 , A61P29/00 , A61K38/02

CPC分类号： A61K31/198 , A23K20/142 , A23K50/50 , A61K31/167 , A61K31/205 , A61K31/223 , A61K31/27 , A61K31/341 , A61K31/381 , A61K31/683 , A61K38/02 , A61K38/05 , A61K38/21 , A61K45/06 , A61P21/00 , A61P29/00 , A61P31/18 , A61P39/00 , A61K31/198 , A61K2300/00 , A61K31/167 , A61K2300/00 , A61K31/27 , A61K2300/00 , A61K31/205 , A61K2300/00 , A61K31/223 , A61K2300/00 , A61K31/381 , A61K2300/00 , A61K31/341 , A61K2300/00 , A61K31/683 , A61K2300/00 , A61K38/21 , A61K2300/00

摘要： Compositions and methods are related to utilizing glycine and N-acetylcysteine for a variety of medical conditions related to reduced levels of glycine, N-acetylcysteine, and/or glutathione, for example, muscle loss such as sarcopenia, HIV infection and other infections, organ damage such as those from diabetes and insulin resistance and diabetic nephropathy, cardiac function and failure such as preventing or improving heart failure, fatty liver, cancer prevention, and other conditions.

6.

发明授权
Methods for treating viral disorders 有权

公开(公告)号：US11701363B2

公开(公告)日：2023-07-18

申请号：US16518226

申请日：2019-07-22

申请人： TRUSTEES OF BOSTON UNIVERSITY

发明人： Susan Park Perrine , Douglas Faller

IPC分类号： A61K31/522 , A61K31/00 , A61K31/166 , A61K31/185 , A61K31/198 , A61K31/223 , A61K31/12 , A61K38/15 , A61K45/06 , A61K38/12

CPC分类号： A61K31/522 , A61K31/00 , A61K31/166 , A61K31/185 , A61K31/198 , A61K31/223 , A61K38/12 , A61K38/15 , A61K45/06

摘要： Disclosed are methods of treating viral disorders via the administration of an inducing agent and an anti-viral agent. In one embodiment, the inducing agent and the anti-viral agent are administered for about five days, and the anti-viral agent is subsequently administered without the inducing agent for an additional period of about sixteen days for a total cycle of about 21 days.

7.

发明公开
MITOCHONDRIAL DYSFUNCTION IMPROVING AGENT 审中-公开

公开(公告)号：US20230147196A1

公开(公告)日：2023-05-11

申请号：US17911965

申请日：2021-03-11

申请人： Jiro TAKATA , Kazuhisa MATSUNAGA , Yoshiharu KARUBE , Katsunori IWASAKI , Shuichi SETOGUCHI , Kazuki TERADA

发明人： Jiro TAKATA , Kazuhisa MATSUNAGA , Yoshiharu KARUBE , Katsunori IWASAKI , Shuichi SETOGUCHI , Kazuki TERADA

IPC分类号： A61K31/27 , A61K31/4406 , C07C271/66 , C07C229/38 , A61K31/223 , C07C309/04 , C07C279/14 , C07C229/46 , C07D213/80 , C07C69/76 , A61K31/235

CPC分类号： A61K31/27 , A61K31/4406 , C07C271/66 , C07C229/38 , A61K31/223 , C07C309/04 , C07C279/14 , C07C229/46 , C07D213/80 , C07C69/76 , A61K31/235 , C07C2601/14

摘要： The object of the present invention is to provide a mitochondrial dysfunction improving agent comprising a vitamin K derivative having a high deliverability to mitochondria.
A mitochondrial dysfunction improving agent, neurodegeneration improving agent, amyotrophic lateral sclerosis improving agent, Alzheimer's disease improving agent, and Parkinson's disease improving agent comprising at least one of a carboxylic acid ester of an active vitamin K represented by a general formula (1) or a salt thereof, and

(wherein, R1 and R2 are a hydrogen atom, respectively, or a substituent selected from glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof; and at least either of R1 and R2 is glycine, N-acyl glycine, N-alkyl glycine, N,N-dialkyl glycine, N,N,N-trialkyl glycine, acyl, dicarboxylic acid hemiester, and salts thereof. R3 is a group represented by a general formula (2), or a general formula (3). n is an integer of 1 to 7)

a mitochondrial dysfunction improving agent, neurodegeneration improving agent, amyotrophic lateral sclerosis improving agent, Alzheimer's disease improving agent, and Parkinson's disease improving agent comprising a carboxylic acid ester of an active vitamin K or a salt thereof (in the general formula (1), R1 and R2 is a carboxylic acid residue selected from a group consisting of R4OOCCH2CH2CO— and R4OOCCH2CH2CH2CO—. R3 represents the above general formula (2) or (3). R4 is a C1-C3 alkyl group.).

8.

发明申请
BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS 审中-公开

公开(公告)号：US20190209592A1

公开(公告)日：2019-07-11

申请号：US16182845

申请日：2018-11-07

申请人： BIOGEN MA INC.

发明人： Jermaine Thomas , Xiaogao Liu , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin M. Guckian , Gnanasambandam Kumaravel , Arthur G. Taveras

IPC分类号： A61K31/695 , A61K31/11 , C07F7/08 , A61K31/165 , A61K31/137 , A61K31/235 , A61K31/223 , C07D401/06 , C07D277/64 , C07D239/74 , C07D217/04 , C07D215/227 , C07C255/54 , C07C47/575 , C07C43/247 , A61K45/06 , A61K31/683 , A61K31/662 , A61K31/517 , A61K31/472 , A61K31/4709 , A61K31/47 , A61K31/445 , A61K31/428 , A61K31/41 , A61K31/404 , A61K31/40 , A61K31/397 , A61K31/337 , A61K31/277 , A61K31/216 , A61K31/197 , A61K31/18 , C07F9/38 , A61K31/085 , C07F9/40 , C07D417/06 , C07D403/06 , C07D305/08 , C07D257/04 , C07D217/24 , C07D215/20 , C07D211/62 , C07D211/60 , C07D209/08 , C07D207/16 , C07D205/04 , C07C311/51 , C07C309/14 , C07C237/52 , C07C237/08 , C07C229/48 , C07C229/46 , C07C229/22 , C07C229/14 , A61K31/401 , A61K31/185 , A61K31/198 , A61K31/222

CPC分类号： A61K31/695 , A61K31/085 , A61K31/11 , A61K31/137 , A61K31/165 , A61K31/18 , A61K31/185 , A61K31/197 , A61K31/198 , A61K31/216 , A61K31/222 , A61K31/223 , A61K31/235 , A61K31/277 , A61K31/337 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/404 , A61K31/41 , A61K31/428 , A61K31/445 , A61K31/47 , A61K31/4709 , A61K31/472 , A61K31/517 , A61K31/662 , A61K31/683 , A61K45/06 , C07C43/247 , C07C47/575 , C07C229/14 , C07C229/22 , C07C229/46 , C07C229/48 , C07C237/08 , C07C237/52 , C07C255/54 , C07C309/14 , C07C311/51 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07D205/04 , C07D207/16 , C07D209/08 , C07D211/60 , C07D211/62 , C07D215/20 , C07D215/227 , C07D217/04 , C07D217/24 , C07D239/74 , C07D257/04 , C07D277/64 , C07D305/08 , C07D401/06 , C07D403/06 , C07D417/06 , C07F7/081 , C07F9/3808 , C07F9/3834 , C07F9/4006

摘要： Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

9.

发明申请
New Pharmaceutical use and Pharmaceutical composition of pyrroloquinoline quinine, its derivatives and/or its salts 审中-公开

公开(公告)号：US20180140596A1

公开(公告)日：2018-05-24

申请号：US15569781

申请日：2016-04-20

申请人： NANJING SHUPENG LIFESCIENCE CO.,LTD

发明人： Chuanjun WEN , Fenyong SUN

IPC分类号： A61K31/4745 , A61P15/00 , A61K45/06

CPC分类号： A61K31/4745 , A61K31/223 , A61K45/06 , A61P15/00 , C07D471/04 , A61K2300/00

摘要： The present invention relates to the use of pyrroloquinoline quinine (PQQ), its derivatives and/or salts for the preparation of drugs for the treatment and/or prevention of endometriosis including adenomyosis, chocolate cyst of ovary, deeply infiltrating endometriosis and other type of endometriosis. In addition, the present invention relates to the use of PQQ in combination with one or more the following antioxidants: N-Acetyl-L-cysteine (NAC), resveratrol, epigallocatechin gallate, vitamin E or vitamin C for the preparation of drugs for inhibiting the proliferation, oxidative stress status, invasion and migration of endometrial stromal cell. The use of PQQ in combination with NAC shows a synergistic effect on inhibiting cell proliferation: significantly inhibiting the proliferation of endometrial stromal cell in vitro; significantly reducing the damaged size of tissue caused by endometriosis in vivo; significantly reducing the infiltration of endometrial stroma and glands; significantly reducing the dose of NAC as well. PQQ is beneficial for fertility, and increases the chances of getting pregnant. PQQ alone or PQQ in combination with NAC generally shows no side effects and will not interfere with pregnancy.